Plain-English translation of NCT07822646 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether — a mineral supplement — can boost the effectiveness of a cancer treatment combination in patients with advanced ovarian cancer. The combination includes an immunotherapy drug (), plus two chemotherapy drugs. Researchers believe the mineral may help your immune system fight the cancer better when added to this treatment.
Advanced ovarian cancer often comes back and becomes resistant to standard treatments. Immunotherapy alone hasn't worked well enough for ovarian cancer because tumors can suppress the immune system. This trial is designed to see if adding this mineral can overcome that suppression and make the existing treatment work better.
You likely qualify if…
You likely don't qualify if…
You would receive treatment every 3 weeks as an outpatient. Half of participants will receive the new mineral-enhanced combination, and half will receive the same combination without the mineral (placebo). You will continue treatment until your cancer shows a second complete response, your disease progresses, you experience unacceptable side effects, or you choose to withdraw. You will need regular blood tests and imaging scans to monitor how well the treatment is working and to watch for side effects.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
China